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A b s t r a c t 
Acute myocardial infarction (MI) provokes a systemic inflammatory response that may contribute to the development of left 
ventricular systolic dysfunction (LVSD) and heart failure (HF). Patients with post-infarct HF with concomitant LVSD have the 
most unfavourable long-term prognosis. Measurement of C-reactive protein (CRP) concentration reflecting an involvement 
of inflammatory pathways in post-infarct myocardial damage offers an attractive strategy to improve risk stratification and 
clinical decision-making for early management of high-risk patients. Despite growing evidence for the prognostic value of CRP 
both as a single factor and as a component of multi-marker approach in MI, CRP measurement is not yet incorporated into 
current guidelines. This may be due to conflicting results reported in existing studies related to various limitations in study 
designs, such as retrospective case control design, prior myocardial damage, CRP measurement with low-sensitivity assays, 
non-homogenous populations with acute coronary syndromes, different treatment strategies, small sample sizes, and the lack 
of left ventricular ejection fraction assessment and long-term clinical and echocardiographic monitoring. As a result, previous 
studies have not provided conclusive evidence of the prognostic value of CRP for post-infarct LVSD or HF. Future studies with 
an adequate design including upstream mediators of inflammation as inflammatory markers are needed to identify the best 
biomarker-based strategies for identifying high-risk patients. Further clinical trials involving anti-inflammatory therapies target-
ing different pathways of inflammatory activation in MI should test the inflammatory hypothesis of post-infarct LVSD and HF. 
Identifying high-risk patients with persistent post-infarct inflammatory response may allow incorporation of pathophysiological 
guidance for implementation of personalised treatment approaches. 
Key words: acute myocardial infarction, left ventricular function, heart failure, echocardiography, C-reactive protein,  
inflammation
Kardiol Pol 2018; 76, 5: 821–829
INTRODUCTION
Despite the progressive decline of mortality in patients with 
myocardial infarction (MI) due to frequent use of reperfusion 
therapies including primary percutaneous coronary interven-
tion (PCI) and other potent evidence-based management, 
post-infarct left ventricular systolic dysfunction (LVSD) and 
heart failure (HF) are still common complications [1–8]. De-
pending on the time point of assessment, diagnostic criteria, 
and therapeutic approach, the prevalence of LVSD post-infarct 
has been estimated at between 15% and 60% [2, 3, 5, 6, 9, 10]. 
LVSD after MI has been identified as a significant marker of 
poor prognosis associated with at least a three- to four-fold 
increase in cardiovascular (CV) mortality and risk of HF [2, 4, 
6, 9, 10]. Decreased left ventricular ejection fraction (LVEF) 
present in echocardiography at hospital discharge after MI is 
a well-recognised marker of early LVSD and an independ-
ent prognostic factor of patient outcomes with regard to 
re-infarction, re-hospitalisation, and cardiac death [2, 4–6, 
9, 10]. Moreover, the incidence of post-infarct HF is still ap-
proximately 28% [1, 2, 6, 7]. HF following an MI affects both 
in-hospital and long-term mortality and morbidity [1, 2, 6–8]. 
Even in the era of commonly used evidence-based therapies, 
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patients with post-infarct HF with concomitant LVSD have 
the most unfavourable long-term prognosis [1, 2, 6–8]. Early 
identification of high-risk patients using proven prognostic 
factors is of utmost importance because it allows for institution 
of preventive strategies. 
Pathophysiology of post-infarct LVSD and HF is multi-
factorial and not clearly understood [8, 11–13]. However, it 
is currently known that the following processes are involved: 
myocardial injury associated with infarct size, myocardial 
stress resulting in neurohormonal activation including sym-
pathetic overstimulation and increased levels of natriuretic 
peptides, left ventricular remodelling (LVR) as a result of myo-
cyte death and abnormal renewal of extracellular matrix, and 
oxidative stress [11, 12]. Current theories for understanding 
the mechanism of damage caused by MI also emphasise the 
role of local and systemic inflammation [12, 14–19]. Acute 
MI is associated with intense inflammatory response, which 
is essential for cardiac repair, involving activation of toll-like 
receptor signalling, complement activation, generation of re-
active oxygen species, cytokine and chemokine upregulation, 
leukocyte and macrophage recruitment, and activation of the 
fibrosis process [14, 15]. However, overactive or prolonged 
post-infarct inflammatory response might trigger further car-
diac damage, resulting in LVR, progressive LVSD, and possibly 
the development of HF [14–18, 20]. 
C-reactive protein (CRP) is the most extensively studied 
biomarker of inflammation in atherosclerotic cardiovascular 
diseases (CVDs) [17–30]. CRP is an acute phase protein that 
is released predominantly by hepatocytes in response to in-
flammatory cytokines such as interleukin (IL)-6 and tumour 
necrosis factor a (TNF-a) [18, 20, 21, 23]. It has become the 
preferred inflammatory biomarker due to its long half-life, 
standardised laboratory assays, and prognostic data based on 
the results of observations from stratifying patients with, or 
at risk of, CVD [13, 17–30]. CRP measurement reflecting the 
involvement of inflammatory pathways of myocardial dam-
age offers an attractive strategy to improve risk stratification 
and clinical decision-making for management of post-infarct 
patients with the highest risk for adverse outcomes [16, 17, 
20, 21, 31]. However, despite growing evidence for the prog-
nostic value of CRP in acute coronary syndromes (ACSs), CRP 
measurement is not yet incorporated into current guidelines 
when defining the standard of care for treatment post-MI. 
CRP FOR CV RISK ASSESSMENT 
There is evidence that inflammation plays a critical role in 
atherogenesis and subsequent atherosclerotic CV events [18]. 
Low-grade inflammation precedes the onset of vascular events 
[24, 27]. Given that even a slightly elevated CRP concentra-
tion (≥ 2 mg/L) can reveal lower levels of inflammation, it may 
be useful for determining further CV risk [24–28, 30]. The 
results of existing studies have shown that CRP concentration 
is associated with the long-term risk of a first atherosclerotic 
CV event in a general population without known CVD and 
with recurrent CV events in patients with established disease 
[22, 24–28, 30, 32]. 
The JUPITER trial confirmed that men and women with 
elevated high-sensitivity CRP concentration (hsCRP) ≥ 2 mg/L 
but with low concentration of low-density lipoprotein cho-
lesterol (LDL-C) are at substantial vascular risk [24]. Based on 
the meta-analysis by Buckley et al. [26], the evidence strongly 
indicates that CRP is associated with events of coronary heart 
disease (CHD). In addition, consistent evidence suggests that 
adding CRP to risk prediction models improves risk stratifica-
tion, particularly among patients who are at intermediate risk 
based on traditional risk factors alone [26]. In a comprehensive 
meta-analysis of more than 50 prospective studies encompass-
ing more than 160,000 subjects without any known history of 
CVD, elevated hsCRP was associated with an increase in risk 
of CHD and CV mortality [30]. Moreover, the magnitude of 
risk associated with one standard deviation in hsCRP eleva-
tion was similar to that observed for such elevation in blood 
pressure or total cholesterol level. 
Based on this evidence, current United States CV screen-
ing guidelines suggest evaluation of hsCRP when additional 
risk information may be needed before the initiation of statin 
therapy [33]. The American College of Cardiology recom-
mends testing hsCRP as class IIa for men > 50 years and 
women > 60 years of age with LDL-C < 130 mg/dL, without 
chronic kidney disease, diabetes, or hormone replacement 
therapy, and class IIb in asymptomatic intermediate-risk 
patients. Current guidelines of the European Society of Car-
diology give hsCRP a class IIb recommendation, stating that 
hsCRP may be measured as part of refined risk assessment 
in patients with unusual or moderate CV risk profiles [34]. 
There is compelling evidence for an association between 
the elevated hsCRP and the long-term (follow-up of 4.8 years) 
risk of acute CV events such as CV death, MI, or stroke in 
patients with stable CHD [28]. Preprocedural hsCRP predicts 
long-term (up to 10-year follow-up) CV outcomes such as mor-
tality, MI, stroke, and stent thrombosis in patients with stable 
CHD undergoing PCI with coronary artery stenting [29, 32]. 
CRP FOR PREDICTION OF ADVERSE  
OUTCOMES IN ACS 
Rapidly accumulating evidence demonstrated the important 
role of CRP concentration for clinical risk stratification in 
patients with ACS with regard to mortality, recurrent MI, 
in-stent restenosis, and composite clinical endpoints [20, 21, 
29, 31, 32, 35–44]. A meta-analysis by He et al. [36] indicated 
that higher early CRP concentration (within the first 72 h of 
ACS onset) increases long-term risk of recurrent CV events 
(including MI) or death, and may be a valuable prognostic 
predictor after ACS, including homogenous populations with 
MI. The finding by Schiele et al. [39] that a high CRP con-
centration combined with the GRACE risk score improves the 
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risk classification represents a useful contribution to clinical 
management of patients with ACS. Recently, Klingenberg et 
al. [40] found an improvement of 9% (or 11% in ST-segment 
elevation myocardial infarction [STEMI] patients) in identifying 
the risk of long-term mortality in patients with ACS referred for 
coronary angiography by applying a multi-marker approach. 
This approach included hsCRP as opposed to the GRACE 
score alone. According to a meta-analysis by Mincu et al. [37], 
preprocedural hsCRP could be a valuable predictor of global 
CV risk in patients with STEMI undergoing PCI and with up to 
36 months of follow-up. The clinical endpoints in that study 
included in-hospital or follow-up all-cause mortality, recur-
rent MI, in-hospital target vessel revascularisation, as well as 
in-hospital or follow-up composite endpoints including death, 
target vessel revascularisation, recurrent MI, and stent-related 
complications. The levels of hsCRP and LDL-C have been 
shown to be independently related to the risk of recurrent 
events in several randomised trials focusing on conservative 
versus intensive statin therapy in patients post ACS [44]. In the 
TIMI 22 PROVE-IT trial, hsCRP measured 30 days after ACS 
was independently associated with the risk of CV death [44]. 
CRP FOR PREDICTION OF POST-INFARCT LVSD 
There is currently some convincing evidence that evaluation 
of CRP concentration in patients with ACS, including those 
with MI, provides prognostic value in predicting the risk of 
developing LVSD in short-term and long-term follow-up 
[35, 37, 39, 41, 43, 45–48]. 
Several studies found a robust relationship between 
in-hospital CRP concentration and the presence of LVSD 
defined as LVEF < 40% at hospital discharge after ACS [35, 
45, 46]. Lim et al. [35] found LVSD at discharge in 32% of 
patients with low-sensitivity CRP concentration measured on 
day 3 after admission in the third tertile of CRP compared 
to 8% with CRP in the first tertile of CRP (p < 0.001). This 
study involved a non-homogenous group of 754 patients with 
ACS, in which 54% of patients had STEMI but only 70% of 
them were treated with PCI. Aggelopoulos et al. [45] showed 
that an increase of 10 mg/L in CRP concentration during 
12 h after admission for ACS independently predicted a 6% 
increase of risk for LVSD at discharge. However, this study 
has limitations that should be taken into consideration, such 
as inclusion of patients with unstable angina (22% of cases), 
retrospective case control design, prior symptoms of CHD 
in about 50% of patients, exclusion of patients with LVEF 
between 40% and 50%, and use of low-sensitivity assay for 
CRP measurement. In a study of 204 patients with STEMI, 
Swiatkiewicz et al. [46] demonstrated that the prevalence 
of LVSD at hospital discharge increased from low to higher 
tertiles of hsCRP at discharge (14.7% vs. 23.5% vs. 45.6%, 
p < 0.001). They concluded that the measurement of hsCRP 
at hospital discharge is a useful marker of LVSD at discharge 
with a greater discriminating value for early LVSD detection 
than B-type natriuretic peptide (BNP) concentration. In 
contrast to earlier studies, the study of Swiatkiewicz et al. 
[46] was performed in a homogenous population with a first 
STEMI undergoing early successful PCI and discharged with 
guideline therapies. It was also based on rigorous selection 
criteria and excluded confounding factors that could affect 
cardiac injury and inflammatory response, including prior 
myocardial damage, active inflammatory process, and ongo-
ing anti-inflammatory therapy. 
In addition, other studies showed significant inverse 
correlations between early CRP concentration and LVEF 
assessed as a continuous variable during hospitalisation for 
ACS [39, 41]. Suleiman et al. [41] observed significantly lower 
LVEF at hospital discharge along with increasing quartiles of 
hsCRP within 12 to 24 h of symptom onset in 1044 patients 
hospitalised for an acute MI. However, factors such as inclu-
sion of patients with various types of MI (70% of patients 
had STEMI), prior MI in 20% of patients, and application of 
reperfusion therapy (thrombolysis or PCI) only in half of the 
entire study group may have biased the results of this study. 
Similarly, in the study including a non-homogenous popula-
tion of 1901 patients with ACS (STEMI was diagnosed in 50% 
of patients and only 30% underwent PCI), Schiele et al. [39] 
found lower LVEF assessed during angiography in patients 
with CRP concentration on admission in the fourth quartile 
compared to lower quartiles (p < 0.001). 
Moreover, several studies demonstrated an inverse re-
lationship between in-hospital CRP measurement and LVEF 
assessment after a long period of observation post-MI [42, 47, 
48]. Ørn et al. [47] observed in 42 patients with first STEMI 
treated by PCI that CRP measured on day 2 and week 1 after 
admission significantly predicted LVEF in cardiac magnetic 
resonance imaging at two months. In 48 patients with STEMI 
undergoing PCI, Mather et al. [48] found hsCRP on day 7 to 
be the strongest independent predictor of LVEF at three 
months assessed by cardiac magnetic resonance imaging. 
Swiatkiewicz et al. [42] observed significantly higher hsCRP 
24 h after admission and lower LVEF six months after hospital 
discharge post-STEMI in the group of patients with LVR at six 
months after discharge compared to patients without LVR. 
The lack of correlation between in-hospital CRP con-
centration and LVEF reported in some studies [49, 50] could 
be caused by the presence of confounding factors such 
as heterogeneity of the investigated population and early 
timing of both CRP concentration measurements and LVEF 
assessment. However, the elevated CRP concentration was 
associated with left ventricular (LV) diastolic dysfunction after 
MI, suggesting that inflammation is related to post-infarct LVR 
independently of LVSF [49]. 
CRP FOR PREDICTION OF POST-INFARCT HF 
There are data indicating a positive relationship between 
elevated CRP levels and the long-term risk of developing 
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new HF in different populations [12, 13, 19]. CRP also has 
a prognostic value in predicting adverse outcome in patients 
with existing HF [12, 13, 19, 51–53]. In addition, a few stud-
ies demonstrated an association between CRP levels and the 
risk of HF in patients with stable CHD [28, 54]. In the PEACE 
trial involving patients with stable CHD, partly after MI and 
receiving modern medical therapy, an elevated hsCRP was 
an independent predictor of new HF over a mean follow-up 
of 4.8 years, even after adjusting for baseline characteristics 
and treatments [28]. In the Heart and Soul Study, increased 
hsCRP was a risk factor for hospitalisation due to HF during 
a three-year follow-up of elderly outpatients with stable CHD, 
including those after MI [54]. This association was independ-
ent of concurrent CHD severity and appeared to be at least 
partially explained by abnormal LV diastolic function and 
increased filling pressures. 
There is some evidence for an association between el-
evated CRP levels and incidence of HF after ACS, indicating 
that CRP may predict hospitalisation for HF [36, 38, 41, 44, 
55]. A meta-analysis by He et al. [36] indicated that early CRP 
concentration may have prognostic value for long-term risk of 
HF assessed as a component of composite clinical endpoint 
after ACS. In the PROVE IT-TIMI 22 trial, the patients with 
ACS, including those with MI and hsCRP > 2 mg/L 30 days 
after ACS stabilisation, had a two-fold higher risk of develop-
ing new or worsening HF in the follow-up of 24 months [44]. 
Studies assessing the prognostic value of CRP in ho-
mogenous populations with MI focused mainly on adverse 
outcomes other than HF, such as mortality or recurrent MI. 
However, some studies have examined the relationship 
between in-hospital CRP concentration and risk of develop-
ment of HF after acute MI [36, 38, 41, 55]. Moreover, only 
a few studies demonstrated an association between CRP and 
the occurrence of HF post-MI as a single clinical endpoint 
[38, 41, 55]. Suleiman et al. [41] showed that early hsCRP is 
a significant marker of long-term development of HF (defined 
as readmission to hospital for the management of HF during 
23 months of follow-up) in 1044 patients with acute MI. In 
addition, hsCRP was shown to add remarkable prognostic 
information compared to conventional risk factors, including 
known clinical predictors of HF, pre-discharge LVEF, and recur-
rent MI during follow-up. Bursi et al. [55] found that hsCRP 
on admission for MI is associated with a significant increase 
in the risk of HF in a one-year follow-up, independently of 
factors such as age, MI severity, comorbidity, previous MI, 
and recurrent ischaemic events. Because hsCRP was not 
correlated with conventional measures of infarct size (such 
as Q waves, ST elevation, and troponin T or peak creatine 
kinase MB levels), its effect was unlikely to be mediated by 
these parameters. The findings of Bursi et al. [55] indicate 
that inflammatory processes play an independent role in the 
development of HF, and hsCRP measurement may assist in 
risk stratification after MI. Unfortunately, in-hospital LVEF was 
not assessed in their study. Another study [38] that exclusively 
included STEMI patients concluded that hsCRP measurement 
has a minimal impact in predicting post-infarct HF. However, 
it was a retrospective analysis of a relatively short one-year 
follow-up of non-optimally treated patients (therapy with 
angiotensin convertase inhibitors was applied in less than 
half of the study population) with only a single-point hsCRP 
measurement on hospital admission. 
CRP IN MULTI-MARKER APPROACH FOR  
PREDICTION OF POST-INFARCT HF 
Currently available biomarkers reflecting several pathobiologi-
cal processes that lead to post-infarct LVSD and HF help to 
identify the specific pathways involved in individual patients 
[12, 13, 19, 53]. Measurements of biomarkers, even those 
that are not independent predictors of risk, may be of clinical 
value because they provide information on the pathogenesis 
of LV damage and HF, and can aid in guiding management of 
treatment. The following biomarkers reflect different ongo-
ing processes in injured myocardium: BNP (neurohormonal 
activation), soluble FMS-like tyrosine kinase receptor (vascular 
remodelling), hsCRP (inflammation), ST2 (myocyte stretch), 
cardiac-specific troponin I (myocyte injury), uric acid (oxida-
tive stress), and creatinine (renal function) [12, 53]. In the 
PROVE IT-TIMI 22 trial, the patients with evidence of both 
persistent inflammation (increased hsCRP) and haemody-
namic stress (elevated BNP) were at the highest risk for future 
HF post-ACS [44]. Thus, the two biomarkers, hsCRP and BNP, 
which reflect the different pathways in LV damage, yield com-
plementary information regarding future risk. However, even 
among patients with low BNP, an increased hsCRP identified 
a sizeable high-risk subgroup within a patient population 
(40.6%) that would otherwise be deemed low-risk for HF or 
CV death. Therefore, combined use of both biomarkers may 
be useful in selecting patients for targeted novel treatments 
to prevent HF after ACS [44]. 
CRP INVOLVEMENT IN MI 
Acute MI provokes an intense inflammatory response that 
contributes to cardiac repair; however, an overactivated 
inflammatory response may be involved in an extension 
of myocardial injury that is essential in the pathogenesis 
of post-infarct LVR, LVSD, and possibly HF [14–18, 20]. In 
response to myocardial necrosis, the inflammatory reaction 
involves the activation of chemokine and cytokine synthesis, 
the adhesion molecule expression on vascular endothelial 
cells, the complement cascade stimulating proinflamma-
tory cytokines release (such as transforming growth factor-a, 
IL-1, and IL-6), and the recruitment of leukocytes. Then, 
the secretion of anti-inflammatory cytokines (such as IL-10, 
transforming growth factor-b) and the modulation of cardiac 
macrophages towards an anti-inflammatory phenotype play 
an important role in suppressing post-infarct inflammatory 
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response. Finally, activation of myofibroblasts and deposi-
tion of matrix proteins promote the healing from myocardial 
infarct, preserving the integrity and geometry of LV. A defect 
in the regulation of the post-infarct inflammatory response 
contributes to the temporal prolongation or spatial expansion 
of the inflammatory reaction, resulting in progressive LVR and 
worsening of LV function. In addition to demonstrating the 
level of inflammation, CRP is a useful biomarker because its 
increased levels indicate an aggravated inflammatory response 
that may predict adverse outcomes post-MI [15–17, 20, 21]. 
In fact, CRP seems to represent both a marker and a media-
tor of inflammatory reaction following MI [15–17, 20, 21]. 
C-reactive protein is released as a response to stimula-
tion by IL-6 produced in the ischaemic zone during acute MI; 
thus, it may indicate the intensity of inflammatory reaction 
[16, 20, 21, 41, 43, 46, 50]. There is evidence that a rapid 
increase in CRP concentration during the first hours of MI is 
the main marker of intensity of inflammation in the infarcted 
area, which is an important determinant of post-infarct LV 
damage [16, 20, 21, 41–43, 46, 50]. It has been documented 
that there is a strong correlation among in-hospital CRP lev-
els, infarct size, and an increase of biochemical markers of 
myocardial necrosis [20, 21, 41–43, 45, 47, 48, 50]. Ørn et 
al. [47] found that CRP concentration on day 2 after PCI was 
significantly correlated with infarct size in cardiac magnetic 
resonance at two months after STEMI, reflecting the degree of 
inflammation within the infarcted area. There is also evidence 
that increased CRP levels may be triggered by the presence of 
microvasculature obstruction following MI, as defined by an 
impairment of flow in damaged capillaries in the central infarct 
zone, resulting in slow diffusion from the necrotic myocardium 
[47, 48]. Ørn et al. [47] found significantly higher CRP levels 
in patients with persistent microvascular obstruction in cardiac 
magnetic resonance on day 2, and especially at week 1 after 
STEMI. In other studies that included patients with other 
types of ACS characterised by smaller areas of necrosis (for 
example, in unstable angina) or a lack thereof, no relationship 
was found between CRP levels and the markers of myocardial 
necrosis [49]. In such circumstances, CRP concentration (usu-
ally without much elevation) may be related to the presence 
of low-degree chronic inflammation in the vascular bed in the 
course of atherosclerosis or vulnerability of unstable plaques 
rather than the extent of myocardial necrosis. 
There is a growing body of basic scientific evidence that 
CRP may directly contribute to myocardial injury during the 
infarction due to the pronecrotic and proatherogenic features 
increasing necrosis expansion [14–18, 21, 56–65]. It was re-
ported that extremely severe inflammatory reaction during MI 
(with CRP ≥ 20 mg/dL) is an independent predictor of suba-
cute cardiac rupture and ventricular aneurysm [16]. Although 
the increase in CRP level may be affected by the infarct size, 
these complications were more often seen in patients with 
a greater increase of CRP concentration compared to the 
maximal creatine kinase level, indicating an extensive infarct 
expansion [16]. In animal studies with an experimental model 
of MI, when an overexpression of human CRP was created, 
adverse LVR and LV dysfunction were demonstrated, although 
the infarct size was similar to the control [56]; whereas the 
inhibition of exogenous CRP with a specific antagonist or 
apheresis decreased the myocardial infarct size and cardiac 
dysfunction [16–18, 57]. CRP binding to phosphocholine 
groups of necrotic myocardium stimulates complement ac-
tivation and increases the deposition of complement in the 
infarcted region, leading to expansion of necrosis in both set-
tings, infarction, and ischaemia-reperfusion injury [15–17, 58, 
59]. In vitro studies showed that CRP increases apoptotic rates, 
macrophage infiltration, expression of chemokines (such as 
monocyte chemoattractant protein 1) in vascular endothelial 
cells, and angiotensin II type I receptors in vascular smooth 
muscle cells [15–17, 60]. CRP also reduces bioavailability of 
nitric oxide, suppressing angiogenesis, and inhibits the dif-
ferentiation, function, and survival of endothelial progenitor 
cells [15–17, 61, 62, 65]. CRP activates various signalling 
cascades, resulting in an increased expression of inflammatory 
cytokines, phagocytic activity, production of reactive oxygen 
species, and promotion of the renin-angiotensin system in the 
myocardium [15–17, 60, 61]. It becomes clear in a diabetic 
cardiomyopathy model that overexpression of CRP activates 
the renin-angiotensin system in the myocardium, enhances 
inflammation and oxidative stress, promotes fibrosis, and ag-
gravates LV dysfunction [63]. 
Increased periprocedural CRP levels may be associated 
with elevated LV end-diastolic pressure in patients undergoing 
coronary angiography, or PCI with coronary artery stenting, 
which by itself can provoke an inflammatory response [29, 
66]. This suggests that greater LV filling pressure, because 
of myocyte stretch during acute MI, may contribute to the 
association of CRP with HF [12, 66]. However, according to 
current literature, it is unlikely that the rapid increase of CRP 
level to such a great extent as seen during MI may be caused 
by the vasculature damage following PCI with an implantation 
of stents in the setting of acute MI [47]. 
The timing of hsCRP measurement in MI appears to 
be important for evaluating its association with subsequent 
CV outcomes [20, 21, 44]. The increase in hsCRP during 
MI may represent the acute-phase reaction to the necrosis 
(when hsCRP is measured within the first 24–72 h of MI), the 
underlying chronic inflammation that preceded MI (when 
hsCRP is measured in the early phase of MI), or persistent 
pro-inflammatory response post-MI (when hsCRP is meas-
ured ≥ one month after MI) [20, 21, 44]. HsCRP ≥ 2 mg/L 
measured ≥ one month after the index MI, by which time 
the initial necrosis and reactive inflammatory process had 
resolved, appears to indicate persistent pro-inflammatory 
activation beyond an acute phase of MI, which may be useful 
for determining further CV risk [23, 25, 44, 67]. Existing results 
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show the ability of hsCRP measured one month post-ACS to 
assess the risk for new HF in stable patients recovering after 
ACS [28, 44]. However, sufficient convincing evidence that 
persistent pro-inflammatory response following MI clearly 
plays a significant role in the development of post-infarct 
LVSD and HF in long-term follow-up is still lacking [67–72]. 
CRP AND ANTI-INFLAMMATORY STRATEGIES 
PREVENTING POST-INFARCT LVSD AND HF 
While inflammation contributes significantly to atheroscle-
rosis, an inhibition of inflammation with decreasing CRP 
concentrations should lower the rates of CV events [23, 25, 
67–72]. Based on the results of the JUPITER trial, target-
ing the “residual inflammatory risk” was recognised as an 
important factor that should be considered during CV risk 
assessment in a healthy population [23–25]. The JUPITER 
study prospectively demonstrated that in a specific popula-
tion (without pre-existing CVD or diabetes and a baseline 
LDL-C < 130 mg/dL, but with evidence of ongoing subclinical 
inflammation, as determined by hsCRP ≥ 2 mg/L), the largest 
reduction of 65% in the hazard of first-ever CV events (such 
as MI, stroke, need for arterial revascularisation, and all-cause 
mortality) after statin therapy was observed in patients who 
achieved both LDL-C < 70 mg/dL and hsCRP < 2 mg/L [24]. 
Ultimately, to test the inflammatory hypothesis of ath-
erosclerosis, it is necessary to directly randomise patients 
to targeted anti-inflammatory therapies and demonstrate 
that pure inflammation inhibition with decreasing CRP but 
without lowering LDL-C reduces CV events [23, 25, 67–72]. 
Currently, it is difficult to advocate CRP as a primary target for 
therapy because there are no existing drugs that specifically 
influence CRP alone. 
Thus, ongoing trials of inflammatory inhibition are focus-
ing on targeting upstream mediators of inflammation (such as 
IL-1b, a pro-inflammatory cytokine that plays multiple roles 
in the atherothrombotic process) as potential treatments for 
CVD, rather than targeting CRP, the downstream biomarker 
[22, 67–72]. In this regard, CRP levels are a surrogate bio-
marker for upstream IL-6 and IL-1 activities. 
Presently, several trials of targeted anti-inflammatory 
therapy in high-risk secondary prevention post-MI are ongo-
ing and other trials are in the planning stages [22, 67–72]. 
The CANTOS and CIRT trials are the large-scale, hard out-
come, randomised, placebo-controlled studies using targeted 
anti-inflammatory agents that reduce hsCRP and IL-6 (but 
have no impact on LDL-C) for an improvement of outcome in 
post-infarct patients [67, 68, 70, 72]. Together, CANTOS and 
CIRT will enroll more than 20,000 patients worldwide and are 
expected to provide sufficient evidence for the inflammatory 
hypothesis of atherothrombosis. 
The CANTOS trial was the first study to demonstrate 
that reducing hsCRP, even in the absence of lipid lowering, 
prevents CV events in patients with stable CHD after previ-
ous MI, who remained at high vascular risk due to persistent 
elevations of hsCRP ≥ 2 mg/L despite contemporary second-
ary prevention strategies [67, 72]. The results of the CANTOS 
trial showed that decreasing inflammation by canakinumab, 
a human monoclonal antibody that selectively neutralises 
IL-1b, significantly reduces recurrent CV events (such as MI, 
stroke, or CV death) by 15% in 3.7 years of follow-up, with 
greater risk reduction among patients with larger hsCRP re-
duction. Moreover, the HsCRP ongoing trial, the sub-study 
of the CANTOS trial, enrolled patients after prior acute MI, 
who also had reduced LVEF < 50% and were symptomatic 
for HF, to prospectively assess exercise capacity, and LVEF and 
LV diastolic function in echocardiography during a 12-month 
follow-up [67, 70]. 
The ongoing CIRT trial is investigating whether taking 
low-dose methotrexate (an anti-inflammatory regimen with-
out significant effects on lipid levels) reduces MI, stroke, and 
CV death (which are the primary clinical endpoints), and also 
hospitalisation for congestive HF (which is the secondary clini-
cal endpoint) in long-term follow-up of patients with prior MI 
and either type 2 diabetes or metabolic syndrome known to 
have high risk on the basis of a persistent pro-inflammatory 
response [68]. Both observational and mechanistic studies 
suggest that low-dose methotrexate has clinically relevant 
anti-atherothrombotic effects and an ability to reduce TNF, 
IL-6, and CRP levels [68]. The potential clinical impact of CIRT 
is important because it has sufficient power to directly address 
HF in the inflammatory hypothesis of post-infarct LV damage. 
Thus, if this goal is successfully achieved, it will lead to major 
new directions for personalised CV treatment to decrease the 
risk of post-infarct HF. 
The VCU-ART3 ongoing trial was designed to examine if 
anakinra, recombinant human IL-1 receptor antagonist, affects 
LVEF during 12 months after STEMI and if it can prevent new 
onset of HF in long-term follow-up [69]. 
If these anti-inflammatory regimens prove to reduce the 
CV events over an average follow-up period of three to five 
years, the results of ongoing studies would provide a novel 
therapeutic approach for the prevention of CV events, includ-
ing HF, in post-infarct patients. 
CONCLUDING REMARKS 
Improving risk stratification post-MI is difficult and challeng-
ing in clinical practice. Biomarkers offer a desirable strategy 
in identifying early high-risk patients for adverse outcomes 
post-MI. Many existing studies show that CRP measurement 
is useful in predicting post-infarct LVSD or HF. Because CRP 
reflects inflammation, it provides additional value to conven-
tional risk factors (such as LVEF, natriuretic peptides, troponin, 
or ST2) representing different pathophysiological processes 
involved in post-infarct myocardial injury. There is evidence 
that CRP, both as a single prognostic marker and as a com-
ponent of a multi-marker strategy, improves risk stratification 
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for long-term prediction of post-infarct LVSD and HF. The 
findings of existing studies have important clinical implica-
tions because they recommend that patients with elevated 
CRP concentration during index MI, especially with existing 
LVSD, should receive more aggressive and personalised medi-
cal management. 
However, despite the growing evidence of the prognos-
tic value of CRP for the prediction of post-infarct LVSD and 
HF, the CRP measurement is not yet considered in current 
guidelines for defining the standards of care treatment in 
MI. This may be due to conflicting results reported in some 
studies related to various limitations in study designs, such as 
retrospective case control design, prior myocardial damage 
or coronary revascularisation, LVEF assessed as a continuous 
variable at an early single time point or not measured, single 
CRP measurement with low-sensitivity assays, non-homog-
enous populations with ACS, different treatment strategies, 
small sample sizes, and the lack of neurohormonal activation 
assessment and long-term clinical and echocardiographic 
monitoring. As a result, the studies with limitations have not 
provided sufficient evidence that CRP can serve as an inde-
pendent predictor, give added value to a suite of multiple 
predictors, or improve reclassification of the predicted risk 
of long-term post-infarct LVSD and HF. There is an unmet 
need for well-designed epidemiological studies aimed at 
assessing the validity of inflammatory markers to determine 
the increased risk of post-infarct LVSD and HF in long-term 
follow-up in homogenous populations with MI after successful 
early PCI when discharged with guideline therapies. 
FUTURE PERSPECTIVES 
There is growing evidence that the phrase “lower is better” 
is true not only for LDL-C but also for biomarkers of inflam-
mation. Thus, identifying high-risk patients with overactive 
or persistent post-infarct inflammatory response may allow 
the incorporation of pathophysiological guidance for imple-
mentation of personalised treatment approaches modifying 
inflammatory and fibrotic responses. Future studies with an 
adequate design and including upstream mediators of in-
flammation as inflammatory markers are needed to validate 
the relationship between an overactive and/or prolonged 
inflammatory activation and adverse outcome post-MI, and 
to identify the best biomarker-based strategies for identifying 
high-risk patients. These studies should be prospective obser-
vational cohort trials with rigorous selection criteria involving 
homogenous MI populations treated with guideline therapies, 
long-term echocardiographic and clinical follow-up, and 
an adequate sample size with high power calculation. The 
study design should specifically exclude confounding factors 
that could affect cardiac injury and inflammatory response, 
including prior myocardial damage, active inflammatory 
process, and ongoing anti-inflammatory therapy. Moreover, 
further clinical trials involving anti-inflammatory therapies 
targeting different pathways of inflammatory activation in MI 
are needed to test the inflammatory hypothesis of long-term 
post-infarct LVSD and HF. 
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